Iveric bio, Still A 5+% Opportunity

11mon ago, source: Hosted on MSN

Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an ...

Astellas to Buy Eye-Drug Maker Iveric Bio for $5.9 Billion

12mon ago, source: Hosted on MSN

(Bloomberg) -- Japanese drugmaker Astellas Pharma Inc. agreed to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, for about $5.9 billion. The deal, which will be ...

Astellas cuts $5.9bn deal to buy Iveric Bio

12mon ago, source: pharmaphorum

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector, The $40-per-share offer values ...

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

10d ago, source:

Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - ...

Ocular Therapeutix CEO Mattessich To Step Down, Dugel To Succeed

11d ago, source:

Ocular Therapeutix, Inc. (OCUL) announced on Monday that President and CEO Antony Mattessich will be stepping down. Mattessich is ...

Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight

1d ago, source:

DelveInsight's Stargardt Disease Market Insights report includes a comprehensive understanding of current treatment practices ...

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

2h ago, source: TMCnet

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that ...

2seventy bio, Inc. (TSVT)

6d ago, source: Yahoo Finance

April 01, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron ...

Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight

3d ago, source:

It has been reported that the prevalence of late-stage AMD increases with age. In Japan, it is observed that age-specific ...

Ocular Therapeutix CEO Mattessich To Step Down, Dugel To Succeed

11d ago, source: Nasdaq

Dugel has previously served in leadership roles such as President of Iveric Bio, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily ...

DelveInsight Business Research, LLP: Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight

2d ago, source: Finanznachrichten

The expected launch of potential therapies may increase the Stargardt disease market size in the coming years, assisted by an increase in the diagnosed prevalent population. Owing to the positive ...